FDA Guidance for Expedited Programs For Serious Conditions
FDA updates guidelines to expedite the development and review of new drugs.
FDA updates guidelines to expedite the development and review of new drugs.
The FDA just released its
Fast Track Designation
Drug to treat a serious disease and fill an unmet medical need.
Key Points
- Designation may be granted on the basis of preclinical or clinical data
- Process designed to facilitate development and expedite review
- Fast Track designated drugs are eligible for: More frequent interactions with FDA (meetings or written correspondence) during drug development Rolling review, whereby companies can submit completed sections of marketing applications for FDA review, rather than waiting until every section is complete
Breakthrough Therapy Designation
Drug intended to treat a serious or life-threatening disease in which there is currently a treatment available.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025